Escin
CAS 6805-41-0
Escin (CAS 6805-41-0) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| Piezo1 PIEZO1 |
Inhibition | 5.800000190734863 pIC50 | 37541373 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| ESCIN | 4065 | SU | MTHSPL |
| escin | 4065 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Escin used for in pharmaceutical contexts?
Escin (CAS 6805-41-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Escin?
No adverse-event association or SIDER side-effect rows are rendered for Escin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Escin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Escin with EU status "permitted".
What clinical phase is Escin in?
No phase 1-4 clinical development badge is rendered for Escin because the matched compound identifier rows do not contain a max-phase value.